WO2000063379A3 - The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof - Google Patents

The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof Download PDF

Info

Publication number
WO2000063379A3
WO2000063379A3 PCT/US2000/010919 US0010919W WO0063379A3 WO 2000063379 A3 WO2000063379 A3 WO 2000063379A3 US 0010919 W US0010919 W US 0010919W WO 0063379 A3 WO0063379 A3 WO 0063379A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
methods
altering
activity
receptor activity
Prior art date
Application number
PCT/US2000/010919
Other languages
French (fr)
Other versions
WO2000063379A2 (en
Inventor
Michael F Jarvis
Kevin J Lynch
Edward C Burgard
Timothy Vanbiesen
Elizabeth A Kowaluk
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to CA002370659A priority Critical patent/CA2370659A1/en
Priority to MXPA01010646A priority patent/MXPA01010646A/en
Priority to JP2000612458A priority patent/JP2004500021A/en
Priority to EP00926289A priority patent/EP1180141A2/en
Publication of WO2000063379A2 publication Critical patent/WO2000063379A2/en
Publication of WO2000063379A3 publication Critical patent/WO2000063379A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The subject invention relates to the P2X3 receptor, methods of modulating the activity of the P2X3 receptor and to uses of these methods. In particular, such methods may be used, for example, to accelerate the rate of resensitization of a desensitized receptor.
PCT/US2000/010919 1999-04-21 2000-04-21 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof WO2000063379A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002370659A CA2370659A1 (en) 1999-04-21 2000-04-21 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
MXPA01010646A MXPA01010646A (en) 1999-04-21 2000-04-21 The p2x3.
JP2000612458A JP2004500021A (en) 1999-04-21 2000-04-21 P2X3 receptor, method of altering P2X3 receptor activity and uses thereof
EP00926289A EP1180141A2 (en) 1999-04-21 2000-04-21 The p2x 3 receptor, methods of altering p2x 3receptor activity and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13033999P 1999-04-21 1999-04-21
US60/130,339 1999-04-21

Publications (2)

Publication Number Publication Date
WO2000063379A2 WO2000063379A2 (en) 2000-10-26
WO2000063379A3 true WO2000063379A3 (en) 2001-11-15

Family

ID=22444222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010919 WO2000063379A2 (en) 1999-04-21 2000-04-21 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof

Country Status (5)

Country Link
EP (1) EP1180141A2 (en)
JP (1) JP2004500021A (en)
CA (1) CA2370659A1 (en)
MX (1) MXPA01010646A (en)
WO (1) WO2000063379A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537169T1 (en) 2005-08-15 2011-12-15 Hoffmann La Roche PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS
US20100221773A1 (en) * 2005-09-30 2010-09-02 Kane Stefanie A Nucleic Acids Encoding a Functional Mammalin Purinoreceptor, P2X3, Methods of Production and Use Thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036539A1 (en) * 1998-01-16 1999-07-22 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor p2x3 and methods of production and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036539A1 (en) * 1998-01-16 1999-07-22 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor p2x3 and methods of production and use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALEXANDER, K. ET AL.: "Allosteric Modulation and Accelerated Resensitization of Human P2X3 Receptors by Cibacron Blue", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 291, no. 3, December 1999 (1999-12-01), pages 1135 - 1142, XP002168399 *
ALEXANDER, K. ET AL.: "Potentiation of ATP-gated human recombinant P2X3 receptor responses by cibacron blue", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, pages 1601, XP000926456 *
COOK, S.P. ET AL.: "A Memory for Extracellular Ca2+ by Speeding Recovery of P2X Receptors from Desensitization", JOURNAL OF NEUROSCIENCE, vol. 18, no. 22, 15 November 1998 (1998-11-15), pages 9238 - 9244, XP002168398 *
GARCIA-GUZMAN, M. ET AL.: "Molecular characterization and pharmacological properties of the human P2X3 purinoceptor", MOLECULAR BRAIN RESEARCH, vol. 47, no. 1-2, July 1997 (1997-07-01), pages 59 - 66, XP002105595 *
MILLER, K.J. ET AL.: "Cibacron blue allosterically modulates the rat P2X4 receptor", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 37, no. 12, December 1998 (1998-12-01), pages 1579 - 1586, XP000926481 *
SAWYNOK, J. & REID, A.: "Peripheral adenosine 5'-triphosphate enhances nociception in the formalin test via activation of a purinergic P2X recptor", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 330, no. 2-3, 9 July 1997 (1997-07-09), pages 115 - 121, XP000926136 *
TSUDA, M. ET AL.: "Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice", BRITISH JOURNAL OF PHARMACOLOGY, vol. 128, no. 7, December 1999 (1999-12-01), pages 1497 - 1504, XP000926133 *
UENO, S. ET AL.: "Cell type-specific ATP-activated responses in rat dorsal root ganglion neurons", BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, no. 2, January 1999 (1999-01-01), pages 429 - 436, XP000926134 *
VIRGINIO, C. ET AL.: "Trinitrophenyl-Substituted Nucleotides Are Potent Antagonists Selective for P2X1, P2X3, and Heteromeric P2X2/3 Receptors", MOLECULAR PHARMACOLOGY, vol. 53, no. 6, June 1998 (1998-06-01), pages 969 - 973, XP002919965 *

Also Published As

Publication number Publication date
MXPA01010646A (en) 2002-05-06
EP1180141A2 (en) 2002-02-20
WO2000063379A2 (en) 2000-10-26
JP2004500021A (en) 2004-01-08
CA2370659A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
HUP0002729A3 (en) 4-haloalkyl-3-heterocyclylpyridines and 4-haloalkyl-5-heterocyclylpyridines, method for the production thereof, agents containing the same and their use as pesticides
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2001079459A3 (en) Polypeptides having haloperoxidase activity
ZA979585B (en) Pesticidal methods, compositions and devices.
WO1999008649A3 (en) Foaming skin cream
ZA982187B (en) Adsorbent construction; and, method.
WO2004043082A3 (en) Complementary beamforming methods and apparatuses
ZA987540B (en) Process for the preparation of stanol esters, and use thereof.
IL130102A (en) Aminoguanidines and alkoxyguanidines as protease inhibitors, pharmaceutical compositions containing the same and processes for preparing the same
WO2001036115A3 (en) Cleaning process which uses ultrasonic waves
AU2003295843A1 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
CA2336375A1 (en) Salt-stable modified starch
AU2001236728A1 (en) Implementation system for continuous welding, method, and products for implementation of the system and/or method
WO1998027058A3 (en) N-piperazin-1-ylphenyl-benzamide derivatives
AU3732400A (en) Clockworks, timepiece and method for operating the same
AU2159797A (en) Substituted pyridines/pyrimidines, process for the preparation thereof and use thereof as pesticides
AU1875199A (en) Safety system and device, as well as safety enhancing process appropriate therefor
WO2000063379A3 (en) The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
ZA969402B (en) Novel oligopeptides, the preparation and use thereof.
ZA9710242B (en) Substituted Nitrogen Heterocycles, processes for their preparation and their use as pesticides.
WO1999010480A3 (en) New tissue-specific calpaines, their production and their use
WO2003093948A3 (en) Dynamic human resources knowledge base and process
EP1018336A4 (en) Carcinostatics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2370659

Country of ref document: CA

Ref country code: CA

Ref document number: 2370659

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010646

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 612458

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000926289

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000926289

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000926289

Country of ref document: EP